Patrick M Sweeney & Associates Inc. Acquires 5,216 Shares of Pfizer Inc. (NYSE:PFE)

Patrick M Sweeney & Associates Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 47,378 shares of the biopharmaceutical company’s stock after purchasing an additional 5,216 shares during the period. Pfizer makes up about 1.0% of Patrick M Sweeney & Associates Inc.’s holdings, making the stock its 21st biggest holding. Patrick M Sweeney & Associates Inc.’s holdings in Pfizer were worth $1,371,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. Tanager Wealth Management LLP acquired a new stake in shares of Pfizer in the third quarter valued at about $233,000. International Assets Investment Management LLC bought a new stake in Pfizer in the third quarter valued at approximately $146,481,000. Heartland Bank & Trust Co increased its position in Pfizer by 8.3% during the 3rd quarter. Heartland Bank & Trust Co now owns 23,068 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 1,777 shares during the period. McAdam LLC raised its holdings in Pfizer by 13.9% during the 3rd quarter. McAdam LLC now owns 21,533 shares of the biopharmaceutical company’s stock worth $623,000 after purchasing an additional 2,628 shares during the last quarter. Finally, Guidance Capital Inc. lifted its position in shares of Pfizer by 2.1% in the 3rd quarter. Guidance Capital Inc. now owns 34,886 shares of the biopharmaceutical company’s stock worth $1,019,000 after purchasing an additional 706 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.1 %

Pfizer stock opened at $28.86 on Thursday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm’s fifty day moving average price is $29.07 and its two-hundred day moving average price is $28.48. The firm has a market capitalization of $163.54 billion, a price-to-earnings ratio of -481.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is currently -2,800.00%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PFE. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday. Finally, Barclays increased their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.